Bayer can have hopes for its drug candidate Asundexian.
The anticoagulant, which at the end of 2023 was not sufficiently effective as a blood thinner to become the successor to the blockbuster Xarelto, which is no longer protected by patent, has now shown positive results in a pivotal clinical study for the prevention of recurrent strokes. The pharmaceutical and agricultural chemical company announced on Sunday that all primary effectiveness and safety goals had been achieved.
In the Phase 3 Oceanic Stroke study, a daily dose of 50 milligrams of Asundexian significantly reduced patients’ risk of suffering another ischemic stroke compared to placebo.
Research director Christian Rommel spoke of an important milestone in promoting innovations in thrombosis prevention. “We are thrilled with these positive topline results.”
Bayer had high hopes for the FXIa inhibitor – with peak sales of more than 5 billion euros per year. Almost two years ago, the drug failed in the crucial clinical study on patients with atrial fibrillation and a risk of stroke, whereupon Bayer shares lost massively in value. Bayer then relied on positive results from the drug in the second indication pursued, stroke prevention.
DOW JONES
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Bayer
The leverage must be between 2 and 20
Advertising